The Yo-Yo Effect After Stopping GLP-1 Drugs: What Does Extended Follow-Up Data Show?

GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) are usually presented through the result achieved by the end of a registration trial's observation period — 68 or 72 weeks of regular use. Far less is said about what happens next, when treatment is discontinued — whether by patient choice, a supply interruption, cost, or reaching a target weight goal.

Two independent extended-follow-up trials — one for semaglutide (the STEP 1 extension), one for tirzepatide (SURMOUNT-4, designed from the outset with a randomized withdrawal phase) — give a consistent answer to this question: stopping the drug leads, in most patients, to significant regain of lost weight within a year, along with a partial reversal of metabolic-parameter improvements.

In other words: a year after stopping the drug, patients regained about two-thirds of the weight they had previously lost, while still retaining a significant, though much smaller than at treatment's peak, net reduction relative to baseline. This isn't a full, 100% return to the starting point, but it also isn't the full therapeutic effect sustained without continued treatment.

The mechanism behind weight regain after stopping GLP-1 drugs isn't a mystery or a sign of treatment failure — it follows directly from the physiology of appetite and body-weight regulation, well described even before the GLP-1 drug era. The body defends its previous, higher body weight using a set of appetite- and energy-expenditure-regulating hormones that, after significant weight loss (regardless of method — diet, surgery, drugs), shift in ways that favor regaining the lost weight: ghrelin (an appetite-stimulating hormone) rises, while leptin and other satiety signals fall disproportionately to the actual loss of fat tissue.

GLP-1 drugs don't remove this mechanism — they pharmacologically counterbalance it, as long as they're present in the body at a sufficient concentration. Semaglutide and tirzepatide have a half-life of roughly 5–7 days, meaning their effect on GLP-1 receptors (and, for tirzepatide, GIP receptors) fades within a few weeks of the last dose. Once that pharmacological counterbalance to hunger and satiety ends, the natural body-weight-defense mechanisms — unchanged by the treatment itself — regain the upper hand, which explains why weight regain after stopping is the rule rather than the exception.

Both trials showed that weight regain after stopping the drug isn't an isolated phenomenon — it's accompanied by a partial reversal of the cardiometabolic improvements achieved during treatment. In a SURMOUNT-4 post-hoc analysis, a greater degree of weight regain after stopping tirzepatide was associated with a greater reversal of favorable changes in waist circumference, blood pressure, non-HDL cholesterol, glycemic parameters, and insulin resistance.

Around the topic of stopping GLP-1 drugs, a fair amount of 'harm reduction' advice has accumulated — how to minimize weight regain after ending treatment. Some of it has reasonable physiological grounding, but little has dedicated, large RCTs testing it specifically in this withdrawal context, rather than in the general context of weight maintenance after any weight-loss method.

Weight regain after stopping GLP-1 drugs isn't an argument against using them — it's an argument for treating obesity as a chronic disease requiring, for many patients, a long-term therapeutic approach rather than a one-time 'course' of treatment. The decision to stop, like the decision to start, should be made together with a doctor, with full awareness of what extended-follow-up data show, rather than assuming an effect once achieved is permanent without further action.